Although FCSL is not attending, we would like to highlight the annual meeting of The American Society of Clinical Oncology (ASCO), May 31-June 4, 2019 in Chicago, Illinois. 

What are MDSC and why are they important?  Simply put, MDSC are pathologically activated myeloid cells.    The name Myeloid Derived Suppressor Cell was first coined in 2007, and in the following years MDSC have become a focus of research and drug development programs.    MDSC are a heterogeneous population of myeloid-derived cells consisting of myeloid progenitors, […]

Although FCSL is not attending, we would like to highlight The 4th International Symposium on Immunotherapy,  organized by the Institute for Cancer Vaccines and Immunotherapy (ICVI), and held May 24-25, 2019 at the Royal Society, London, England UK.

Our immune system is in a constant “molecular arms race” to stave off pathogenic invaders that want take up residence in our bodies. This is a battle where the microbes may gain the upper hand for a time, only to be outmaneuvered by our immune cells (Jonas, 2019).  For an immune cell, one strategy and […]

Uncovering Mechanisms of Immune-Based Therapy in Cancer and Autoimmunity (B3) 18th – 22nd February 2019 Beaver Run Resort, Breckenridge, Colorado, United States Although FCSL will not be attending, we would like to highlight the following meeting which marks the significant progress in the field of immunology over the past two decades.  Therapeutic agents such as anti-TNF, […]

The Natural Killer Cell Cytotoxicity Assay Natural killer cells (NK cells) are a subset of blood lymphocytes that play an essential role in immunosurveillance and the innate immune response.   As a first line of defense, NK cells specifically recognize virally infected and malignantly transformed cells and target them for killing and removal.   And they work […]

When:  February 2-6, 2019 Where:  Walter E. Washington Convention Center, Washington DC Website: The Society for Laboratory Automation and Screening (SLAS) holds its annual meeting February 2-6, 2019 in Washington D.C.   The meeting includes advances in many leading-edge technologies including flow cytometry.

Flow Contract Site Laboratory (FCSL) would like to introduce Darcey L. Clark as an addition to our staff as our Chief Scientific Officer. Darcey L. Clark is a senior biotechnology professional with 20+ years of experience in non-clinical drug development (large and small molecule).